Results 131 to 140 of about 108,375,652 (210)

Antiemetic-associated QT prolongation: a clinical review and risk-stratified prescribing framework for long QT syndrome. [PDF]

Eur Heart J Cardiovasc Pharmacother
Moustafa AT, Dabash O, Panigrahi PK, Khan HR.   +3 more
europepmc   +1 more source

Managing trastuzumab deruxtecan-related adverse events in patients with metastatic breast cancer: insights from a worldwide survey of the Hermione EDUcational project. [PDF]

Support Care Cancer
Cazzaniga ME, Aapro M, Bianchi MA, Charalambous A, Cortesi L, Costa L, Fashing P, Garcia ABR, Gilles F, Hennessy B, Iihara H, Lapuente M, Ma F, Matesanz IR, McCann KE, Park YH, Rugo HS, Sakai H, Strasser F, Walbaum B, Wang S.   +20 more
europepmc   +1 more source

Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetant. [PDF]

Breast
Pogoda K, Arecco L, Lambertini M.
europepmc   +1 more source

Emerging pharmacological targets in migraine therapy: CGRP and beyond. [PDF]

Front Pharmacol
Atraszkiewicz D, Dahiya D.
europepmc   +1 more source

Aprepitant, a Neurokinin-1 Receptor Antagonist, as a Disruptive Drug for the Treatment of Pediatric Cancer. [PDF]

J Clin Med
Rosso M, Alcaide C, Muñoz M.
europepmc   +1 more source

Netupitant versus aprepitant: model-predicted neurokinin-1 receptor occupancy and implications for long-delayed nausea and vomiting prevention. [PDF]

Support Care Cancer
Iihara H, Bianchini G, Aapro M, Licata L, Bernareggi A, Navari RM, Park YH, Jordan K, Vidal M, Scotté F, Roeland EJ, Schwartzberg L, Rugo HS.   +12 more
europepmc   +1 more source

Intracellular pocket and ICL2 motifs govern G-protein coupling bias in NK₁ receptor (TACR1) and NK₂ receptor (TACR2). [PDF]

J Biol Chem
Petersen JE, Pavlovskyi A, Madsen JJ, Schwartz TW, Frimurer TM, Olsen OH.   +5 more
europepmc   +1 more source

Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications. [PDF]

J Endocr Soc
Boretti E, Dogné JM, Douxfils J.
europepmc   +1 more source

Elinzanetant: Defining the Role of Dual Neurokinin-1 and Neurokinin-3 Receptor Antagonism for Management of Vasomotor Symptoms in Menopause. [PDF]

J Menopausal Med
Teli V, Teli A.
europepmc   +1 more source

Structure and activity relationship of sendide, a neurokinin-1 receptor antagonist.

Japanese Journal of Pharmacology, 1996
Makoto Inoue, Tsukasa Sakurada, Koichi Tan-No, Shinobu Sakurada, Chikai Sakurada, Masataka Ohba, Kensuke Kisua   +6 more
openaire   +1 more source